The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A randomized, phase Ib/II trial of rilotumumab (AMG 102; ril) or ganitumab (AMG 479; gan) with panitumumab (pmab) versus pmab alone in patients (pts) with wild-type (WT) KRAS metastatic colorectal cancer (mCRC): Primary and biomarker analyses.
C. Eng
No relevant relationships to disclose
E. Van Cutsem
Research Funding - Amgen
E. Nowara
No relevant relationships to disclose
A. Swieboda-Sadlej
No relevant relationships to disclose
N. C. Tebbutt
Consultant or Advisory Role - Amgen (U)
Research Funding - Amgen
E. P. Mitchell
Consultant or Advisory Role - Amgen
Honoraria - Amgen
Research Funding - Amgen
I. Davidenko
No relevant relationships to disclose
K. Oliner
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
L. Chen
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
J. Huang
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
I. McCaffery
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
E. Loh
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
D. Smethurst
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
J. Tabernero
Consultant or Advisory Role - Amgen
Honoraria - Amgen
Expert Testimony - Amgen (U)